|
TINF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.71462843923109E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.30655511252098E-13 |
| Normal-vs-Stage2 |
1.56669999995529E-06 |
| Normal-vs-Stage3 |
3.28129745597039E-11 |
| Normal-vs-Stage4 |
7.22260029561994E-10 |
| Stage1-vs-Stage2 |
9.208400E-01 |
| Stage1-vs-Stage3 |
8.622600E-01 |
| Stage1-vs-Stage4 |
3.364200E-01 |
| Stage2-vs-Stage3 |
8.445600E-01 |
| Stage2-vs-Stage4 |
4.531400E-01 |
| Stage3-vs-Stage4 |
4.593600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.61686244790371E-12 |
| Normal-vs-AfricanAmerican |
1.35680000001859E-06 |
| Normal-vs-Asian |
6.93879997903935E-09 |
| Caucasian-vs-AfricanAmerican |
9.791600E-01 |
| Caucasian-vs-Asian |
4.158200E-01 |
| AfricanAmerican-vs-Asian |
5.841000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.68887126505979E-12 |
| Normal-vs-Female |
8.58313420337709E-13 |
| Male-vs-Female |
1.089800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.25319754573638E-11 |
| Normal-vs-Age(41-60Yrs) |
2.18025597575888E-12 |
| Normal-vs-Age(61-80Yrs) |
2.46547227078509E-12 |
| Normal-vs-Age(81-100Yrs) |
1.286190E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.042000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.174610E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.067200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.717640E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.635000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.987570E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.485000E-01 |
| Classical-VS-Follicular |
1.74365999999759E-05 |
| Classical-VS-Other |
2.745800E-02 |
| Classical-VS-Normal |
8.16020029326125E-10 |
| Tall-VS-Follicular |
2.034300E-02 |
| Tall-VS-Other |
2.765400E-01 |
| Tall-VS-Normal |
2.22619999989959E-07 |
| Follicular-VS-Other |
7.532200E-01 |
| Follicular-VS-Normal |
6.43929354282591E-15 |
| Other-VS-Normal |
1.292230E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66555658154266E-12 |
| Normal-vs-N1 |
1.61239999130203E-09 |
| N0-vs-N1 |
2.691000E-01 |
|
|
